Current and Future Neuropharmacological Options for the Treatment of Essential Tremor

(E-pub Ahead of Print)

Author(s): Hortensia Alonso-Navarro, Elena García-Martín, José A.G. Agúndez, Félix Javier Jiménez-Jiménez*.

Journal Name: Current Neuropharmacology

Become EABM
Become Reviewer


Background: Essential tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options arisen from drugs tested in experimental models of ET or from neuropathological data.

Methods: Literature search on the pharmacology of essential tremor using PubMed Database from 1966 to July 31, 2019.

Results and conclusions: To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABAA receptors, glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.

Keywords: Essential tremor, Neuropharmacology, Beta-blockers, Primidone, Antiepileptic drugs, Gap-junction blockers, Experimental treatment

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1570159X18666200124145743
Price: $95

Article Metrics

PDF: 8